COVID-19 Long Haul Syndrome – Exploring the Controversy and Pathways Forward

COVID-19 Long-Haul Syndrome Expert Panel Discussion with Dr. David Brady

Dr. Brady was again asked to organize and chair an expert panel discussion for the Integrative Healthcare Symposium (2022) in New York City this past February 2022. This panel brought together world experts in COVID-19 Long-Haul Syndrome from various fields, to include basic translational science, laboratory diagnostics, clinical practice, and the direct patient experience. This Long-Haul panel discussion lead off the entire conference in the main ballroom on the morning of February 17, 2022 and featured Bruce Patterson, MD, Richard Horowitz, MD, Tom Fabian, PhD, Gez Medinger, and Dr. David Brady. To learn more please see video HERE

COVID-19 Long-Haul Panel

Event:   Integrative Healthcare Symposium (IHS)-2022

Title:                    COVID-19 Long Haul Syndrome-Exploring the Controversies and Pathways

Chair/Moderator David M. Brady, ND

Panelists:            Bruce Patterson, MD
Richard Horowitz, MD
Tom Fabian, PhD
Gez Medinger


Post-COVID-19 Syndrome, often known as Long-Haul Syndrome, represents a complex multi-factorial phenomenon that is being observed clinically in a significant percentage of those individuals that have recovered from initial acute COVID-19, but have far from fully recovered. There are millions of people suffering from ongoing persistent fatigue and malaise, joint pain and body aches, tachycardia, headaches, brain-fog, strange neurological symptoms, and many more problems long after the initial illness associated with SARS-CoV2 has passed. They are being observed both in the developed and under-developed world. It is becoming very clear that Long-Haul Syndrome is a complex entity and may represent the result of a “perfect storm” of biological and environmental factors and that a systems-biology
approach, utilizing a wider-lens perspective, will be required as these subjects are approached clinically. There exists considerable gaps between the focus of the initial research into this phenomenon and the current approach to these conditions in standard clinical medicine, with standard interventions based predominantly on symptom control. This expert panel with review the various hypotheses proposed to explain this emerging post-pandemic epidemic. Discussion elements will include an exploration of why some go on to suffer from long-term
symptoms, and many do not. The role of the immune system and its complicated reaction and adaptations to SARS-CoV-2, post-viral vascular/endothelial/glycocalyx aberrations, alterations in the GI microbiota and microbial metabolites, molecular mimicry, and other aspects of pathogenesis will also be explored along with how these may serve as leverage points for new diagnostics and clinical interventions.


1. Appreciate the current epidemiologic trends in
post-COVID Long Haul Syndrome.

2. Understand the linkage and association between Long-Haul and factors including immunological cytokine patterns, vascular abnormalities, the GI microbiota, ongoing stealth infections, molecular mimicry, and other

3. Appreciate the available emerging clinical
laboratory testing related to long-haul diagnosis, and clinical management, including complex cytokine pattern analysis, qPCR molecular-based evaluation of the GI microbiota, antigen testing, and others.

4. Understand the available evidence-based drug, nutritional, lifestyle and complementary therapeutic interventions for autoimmune disorders.

5. Become enlightened on the “patient experience”
and strategies of collaborative care for patients with long-haul syndrome.

General Outline:

Opening statement and panelist introductions by Dr.

5-minute opening statement by each panelist outlining
their specific interests and areas of clinical or research focus regarding long-haul syndrome.

Questions posed to individual panelists and the collective from panel moderator (To be further
developed and proposed

Q&A with audience members



Dr. David M. Brady, Fairfield, CTDr. David M. Brady almost 30-years of experience as an integrative practitioner and over 25 years in health sciences academia. He is a licensed naturopathic medical physician in Connecticut and Vermont, is board certified in functional medicine and clinical nutrition, and is a Fellow of the American College of Nutrition.

He maintains a private practice, Whole Body Medicine, in Fairfield, CT (USA). Dr. Brady is also the Chief Medical Officer for Designs for Health, Inc. and Diagnostic Solutions Labs, LLC, and is an expert consultant to the nutritional supplement and clinical laboratory industries.



Call Now Button